Logo

BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma

Share this

BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma

Shots:

  • The P-II/III RELATIVITY-047 (CA224-047) study involves assessing the FD combination of relatlimab (160 mg) + Opdivo (480mg) vs Opdivo (480mg- IV- q4w) alone in 714 patients in a ratio (1:1) with previously untreated metastatic or unresectable melanoma
  • The study met its 1EPs of the PFS while the follow-up for 2EPs of OS and ORR is ongoing. The combination was well-tolerated
  • Relatlimab is a fully human LAG3-specific Ab- currently being evaluated in clinical trials in combination with other agents in a variety of tumor types

 ­ Ref: BusinessWire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions